Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mizolastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 19/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 10/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 8/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 17/20 | 0.75 |
| ▸ | HTR3A | P46098 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mizolastine SCHEMBL29369194 | 1.00 | HRH1 (1.00) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| Mizolastine SCHEMBL29256081 | 0.99 | HRH1 (0.98) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| Mizolastine SCHEMBL28266367 | 0.97 | HRH1 (0.95) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| Mizolastine SCHEMBL4443891 | 0.85 | HRH1 (0.73) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| SCHEMBL18597171 | 0.83 | HRH1 (0.74) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| Mizolastine SCHEMBL6273027 | 0.82 | HRH1 (0.84) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| SCHEMBL12668369 | 0.82 | HRH1 (0.69) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| SCHEMBL21984846 | 0.81 | HRH1 (0.69) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| SCHEMBL12045361 | 0.81 | HRH1 (0.68) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| SCHEMBL18388464 | 0.81 | HRH1 (0.78) | HRH1KCNH2CHRM1ADRA2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9379 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6436924-B1 | — | — | None | — | — | US | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4691568-A2 | LOW-DOSE BRIMONIDINE COMBINATIONS AND USES THEREOF | Eye Therapies, LLC (US) | 2026-02-11 | — | — | EP | claimed |
| US-20250275951-A1 | DRUGS TARGETING INFLAMMATION FOR THE TREATMENT OF OSTEOARTHRITIS AND OTHER INFLAMMATORY DISEASES | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2025-09-04 | — | — | US | claimed |
| EP-4565206-A1 | OPHTHALMIC COMPOSITION COMPRISING PILOCARPINE AND A REDNESS REDUCTION AGENT | Bausch + Lomb Ireland Limited (IE) | 2025-06-11 | — | — | EP | claimed |
| WO-2025066935-A1 | COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) | 2025-04-03 | — | — | WO | claimed |
| CN-119707917-A | Preparation method of mizolastine intermediate | 沈阳三九药业有限公司 | 2025-03-28 | — | — | CN | claimed |
| WO-2024229174-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2024-11-07 | — | — | WO | claimed |
| EP-3508501-B1 | USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS | H LUNDBECK AS (DK) | 2024-11-06 | — | — | EP | claimed |
| CN-1233179-A | Treatment of upper airway allergic responses with a combination of histamine receptor antagonists | SCHERING CORP (US) | 1999-10-27 | — | — | CN | claimed |
| EP-0920315-A1 | TREATMENT OF UPPER AIRWAY ALLERGIC RESPONSES WITH A COMBINATION OF HISTAMINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 1999-06-09 | — | — | EP | claimed |
| EP-0906101-A1 | SLOW-RELEASE PHARMACEUTICAL FORMULATIONS CONTAINING MIZOLASTIN | SYNTHELABO (FR) | 1999-04-07 | — | — | EP | claimed |
| WO-1999015203-A1 | USE OF COMBINATIONS COMPRISING NON-SEDATING ANTIHISTAMINES AND ALPHA-ADRENERGIC DRUGS FOR THE TOPICAL TREATMENT OF RHINITIS/CONJUNCTIVITIS AND COLD, COLD-LIKE AND/OR FLU SYMPTOMS | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1999-04-01 | — | — | WO | claimed |
| CN-1212624-A | Sustained release pharmaceutical formulation containing mizolastine | SYNTHELABO (FR) | 1999-03-31 | — | — | CN | claimed |
| EP-0903151-A1 | Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms | ASTA Medica Aktiengesellschaft (DE) | 1999-03-24 | — | — | EP | claimed |
| US-5869479-A | ADMINISTERING HISTAMINE H1 RECEPTOR ANTAGONISTS AND HISTAMINE H3 RECEPTOR ANTAGONISTS; NASAL DECONGESTANT WITHOUT THE NERVOUS SYSTEM OR CARDIOVASCULAR SIDE EFFECTS | SCHERING CORPORATION (US) | 1999-02-09 | — | — | US | claimed |
| WO-1998047511-A1 | USE OF MIZOLASTINE FOR PREPARING A MEDICINE FOR TREATING INFLAMMATION | SANOFI-SYNTHELABO (FR) | 1998-10-29 | — | — | WO | claimed |
| WO-1998006394-A1 | TREATMENT OF UPPER AIRWAY ALLERGIC RESPONSES WITH A COMBINATION OF HISTAMINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 1998-02-19 | — | — | WO | claimed |
| WO-1997032584-A1 | SLOW-RELEASE PHARMACEUTICAL FORMULATIONS CONTAINING MIZOLASTIN | SYNTHELABO (FR) | 1997-09-12 | — | — | WO | claimed |